{"id":"iguratimod","rwe":[],"tags":[{"label":"Small Molecule","category":"modality"},{"label":"Macrophage migration inhibitory factor","category":"target"},{"label":"MIF","category":"gene"},{"label":"Active","category":"status"},{"label":"Rheumatoid arthritis","category":"indication"}],"phase":"marketed","safety":{"safetySignals":[{"llr":207.984,"date":"","count":56,"signal":"Pneumocystis jirovecii pneumonia","source":"DrugCentral FAERS","actionTaken":"Reported 56 times (LLR=208)"},{"llr":151.264,"date":"","count":59,"signal":"Interstitial lung disease","source":"DrugCentral FAERS","actionTaken":"Reported 59 times (LLR=151)"},{"llr":123.362,"date":"","count":26,"signal":"Lymphoproliferative disorder","source":"DrugCentral FAERS","actionTaken":"Reported 26 times (LLR=123)"},{"llr":55.707,"date":"","count":9,"signal":"Adult T-cell lymphoma/leukaemia","source":"DrugCentral FAERS","actionTaken":"Reported 9 times (LLR=56)"},{"llr":51.595,"date":"","count":17,"signal":"Pneumonia bacterial","source":"DrugCentral FAERS","actionTaken":"Reported 17 times (LLR=52)"},{"llr":47.599,"date":"","count":26,"signal":"Herpes zoster","source":"DrugCentral FAERS","actionTaken":"Reported 26 times (LLR=48)"}],"commonSideEffects":[]},"trials":[],"aliases":[],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=IGURATIMOD","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T01:37:01.272980+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T01:37:06.837974+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=IGURATIMOD","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T01:37:07.211696+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Cyclooxygenase-2 inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:37:08.340780+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2107455/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:37:08.000582+00:00"}},"allNames":"kolbet","offLabel":[],"synonyms":["iguratimod","kolbet","careram","T-614"],"timeline":[{"date":"2012-06-29","type":"positive","source":"DrugCentral","milestone":"PMDA approval"}],"approvals":[{"date":"2012-06-29","orphan":false,"company":"","regulator":"PMDA"}],"brandName":"Kolbet","ecosystem":[{"indication":"Rheumatoid arthritis","otherDrugs":[{"name":"abatacept","slug":"abatacept","company":"Bristol Myers Squibb"},{"name":"aceclofenac","slug":"aceclofenac","company":""},{"name":"acetylsalicylic acid","slug":"acetylsalicylic-acid","company":"Endo Pharms"},{"name":"adalimumab","slug":"adalimumab","company":"Abbvie Inc"}],"globalPrevalence":18000000}],"mechanism":{"target":"Macrophage migration inhibitory factor","targets":[{"gene":"MIF","source":"DrugCentral","target":"Macrophage migration inhibitory factor","protein":"Macrophage migration inhibitory factor"}],"modality":"Small Molecule","explanation":"","oneSentence":"","technicalDetail":"Kolbet binds to MIF, inhibiting its enzymatic activity and downstream signaling pathways, which are involved in the regulation of immune responses and inflammation."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/4894","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=IGURATIMOD","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=IGURATIMOD","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T13:55:29.861484","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:37:09.640435+00:00","fieldsConflicting":2,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"hexachlorophene","drugSlug":"hexachlorophene","fdaApproval":"1949-04-19","patentStatus":"Unknown","relationship":"same-target"},{"drugName":"histamine","drugSlug":"histamine","fdaApproval":"1939-04-25","patentStatus":"Unknown","relationship":"same-target"},{"drugName":"levothyroxine","drugSlug":"levothyroxine","fdaApproval":"2000-08-21","patentExpiry":"Sep 17, 2039","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"metaraminol","drugSlug":"metaraminol","fdaApproval":"1954-09-29","genericCount":5,"patentStatus":"Off-patent — generic available","relationship":"same-target"}],"genericName":"iguratimod","indications":{"approved":[{"name":"Rheumatoid arthritis","source":"DrugCentral","snomedId":69896004,"regulator":"FDA","usPrevalence":1500000,"globalPrevalence":18000000,"prevalenceMethod":"curated","prevalenceSource":"Lancet Rheumatology, 2023"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"hexachlorophene","brandName":"hexachlorophene","genericName":"hexachlorophene","approvalYear":"1949","relationship":"same-target"},{"drugId":"histamine","brandName":"histamine","genericName":"histamine","approvalYear":"1939","relationship":"same-target"},{"drugId":"levothyroxine","brandName":"levothyroxine","genericName":"levothyroxine","approvalYear":"2000","relationship":"same-target"},{"drugId":"metaraminol","brandName":"metaraminol","genericName":"metaraminol","approvalYear":"1954","relationship":"same-target"}],"trialDetails":[{"nctId":"NCT05789030","phase":"NA","title":"Treatment Strategies for IgG4-RD Patients With Superficial Organ Involvement","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2022-07-01","conditions":["Autoimmune Diseases"],"enrollment":60,"completionDate":"2026-04-30"},{"nctId":"NCT07115641","phase":"NA","title":"Clinical Trial of Huoluo Pills Combined With Iguratimod Tablets in the Treatment of Rheumatoid Arthritis","status":"NOT_YET_RECRUITING","sponsor":"Wangjing Hospital, China Academy of Chinese Medical Sciences","startDate":"2025-08-11","conditions":["Rheumatoid Arthritis"],"enrollment":240,"completionDate":"2026-08-31"},{"nctId":"NCT07057778","phase":"PHASE2","title":"Iguratimod Plus Low-dose Rituximab vs Low-dose Rituximab in Corticosteroid-resistant or Relapsed ITP","status":"NOT_YET_RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2025-07-01","conditions":["Immune Thrombocytopenia (ITP)"],"enrollment":120,"completionDate":"2027-07-01"},{"nctId":"NCT06945666","phase":"PHASE4","title":"A Study of Iguratimod in Combination With Tofacitinib in RA Patients","status":"NOT_YET_RECRUITING","sponsor":"Jie Chang","startDate":"2025-08-01","conditions":["Rheumatoid Arthritis (RA"],"enrollment":200,"completionDate":"2027-05-31"},{"nctId":"NCT03660059","phase":"PHASE3","title":"A Study to Assess Safety and Efficacy of ASP015K in Participants With Rheumatoid Arthritis (RA) Who Had an Inadequate Response or Intolerance to Methotrexate (MTX)","status":"COMPLETED","sponsor":"Astellas Pharma China, Inc.","startDate":"2018-09-27","conditions":["Rheumatoid Arthritis (RA)"],"enrollment":385,"completionDate":"2021-11-02"},{"nctId":"NCT04981145","phase":"PHASE4","title":"The Efficacy and Safety of Iguratimod (IGU) in the Treatment of Primary Sjögren's Syndrome","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2022-01-14","conditions":["Primary Sjögren's Syndrome"],"enrollment":78,"completionDate":"2025-07"},{"nctId":"NCT06146972","phase":"PHASE4","title":"Efficacy Study of Iguratimod Combined With Tofacitab in Patients With RF Positive/Negative Rheumatoid Arthritis","status":"RECRUITING","sponsor":"Yanfeng Hou","startDate":"2021-06-01","conditions":["Rheumatoid Arthritis","Therapy"],"enrollment":117,"completionDate":"2024-05-31"},{"nctId":"NCT06244628","phase":"PHASE3","title":"Safety and Efficacy of Iguratimod in the Treatment of Chronic GVHD","status":"UNKNOWN","sponsor":"Xuzhou Medical University","startDate":"2024-01-10","conditions":["cGVHD"],"enrollment":20,"completionDate":"2025-12-31"},{"nctId":"NCT04928066","phase":"PHASE4","title":"The Efficacy and Safety of Tofacitinib (TF) With Iguratimod (IGU) on RA","status":"COMPLETED","sponsor":"Qilu Hospital of Shandong University","startDate":"2020-03-01","conditions":["Arthritis, Rheumatoid"],"enrollment":100,"completionDate":"2023-07-30"},{"nctId":"NCT03855007","phase":"PHASE4","title":"The Clinical Efficacy and Safety of Iguratimod in RA and Early RA Patients for 6 Months Treatment","status":"COMPLETED","sponsor":"Qilu Hospital of Shandong University","startDate":"2016-01-01","conditions":["Arthritis, Rheumatoid"],"enrollment":400,"completionDate":"2023-10-31"},{"nctId":"NCT05803135","phase":"PHASE4","title":"Iguratimod Combined With Tofacitinib in the Treatment of Rheumatoid Arthritis","status":"UNKNOWN","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2023-03-31","conditions":["Rheumatoid Arthritis"],"enrollment":138,"completionDate":"2025-12-30"},{"nctId":"NCT05626348","phase":"PHASE4","title":"The Clinical Efficacy of Immunomodulators in RA Patients","status":"RECRUITING","sponsor":"Qilu Hospital of Shandong University","startDate":"2021-12-22","conditions":["Arthritis, Rheumatoid"],"enrollment":400,"completionDate":"2026-12-31"},{"nctId":"NCT05281068","phase":"PHASE2","title":"The Combination of Iguratimod and Danazol as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia","status":"UNKNOWN","sponsor":"Peking University People's Hospital","startDate":"2021-09-01","conditions":["ITP","Immune Thrombocytopenia"],"enrollment":120,"completionDate":"2023-12-30"},{"nctId":"NCT05302024","phase":"PHASE2","title":"Efficacy and Safety of Iguratimod in the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia","status":"UNKNOWN","sponsor":"Peking University People's Hospital","startDate":"2022-03-22","conditions":["Immune Thrombocytopenia"],"enrollment":100,"completionDate":"2023-12-12"},{"nctId":"NCT05216757","phase":"PHASE2,PHASE3","title":"Efficacy and Safety of Iguratimod in Patients With Hand Osteoarthritis (ESIGO)","status":"UNKNOWN","sponsor":"Peking University People's Hospital","startDate":"2022-03","conditions":["Hand Osteoarthritis","Inflammatory Arthritis"],"enrollment":150,"completionDate":"2024-12"},{"nctId":"NCT03893136","phase":"","title":"The Registry Study of Takayasu Arteritis in East China","status":"RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2016-11-01","conditions":["Takayasu Arteritis","Mechanisms, Defense","Pregnancy Related","Treatment Refusal","Outcome"],"enrollment":1000,"completionDate":"2026-05-31"},{"nctId":"NCT04830644","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of Iguratimod Compared to Placebo in Patients With Active Primary Sjogren's Syndrome.","status":"UNKNOWN","sponsor":"Jiangsu Simcere Pharmaceutical Co., Ltd.","startDate":"2021-03-22","conditions":["Primary Sjögren Syndrome"],"enrollment":144,"completionDate":"2022-06"},{"nctId":"NCT04927000","phase":"PHASE4","title":"The Role of Tofacitinib in Steroid Withdrawal in Rheumatoid Arthritis","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2021-05-31","conditions":["Rheumatoid Arthritis"],"enrollment":170,"completionDate":"2023-12-30"},{"nctId":"NCT01554917","phase":"PHASE4","title":"A Study of Iguratimod in Patients With Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Jiangsu Simcere Pharmaceutical Co., Ltd.","startDate":"2012-05","conditions":["Rheumatoid Arthritis"],"enrollment":1759,"completionDate":"2015-08"},{"nctId":"NCT04515706","phase":"NA","title":"Iguratimod in Systemic Sclerosis","status":"UNKNOWN","sponsor":"RenJi Hospital","startDate":"2021-01-01","conditions":["Systemic Sclerosis, Diffuse"],"enrollment":20,"completionDate":"2024-01-31"},{"nctId":"NCT02936375","phase":"PHASE2","title":"The Iguratimod Effect on Lupus Nephritis (IGeLU)","status":"UNKNOWN","sponsor":"RenJi Hospital","startDate":"2017-09-07","conditions":["Lupus Nephritis"],"enrollment":120,"completionDate":"2021-11"},{"nctId":"NCT01850966","phase":"","title":"Investigation of the Safety and Efficacy of Iguratimod in Patients With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Eisai Co., Ltd.","startDate":"2012-09-12","conditions":["Rheumatoid Arthritis"],"enrollment":2747,"completionDate":"2014-04-13"},{"nctId":"NCT02839941","phase":"NA","title":"Iguratimod in Kidney Transplant Recipients","status":"UNKNOWN","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2016-08","conditions":["Kidney Transplantation"],"enrollment":60,"completionDate":"2019-07"},{"nctId":"NCT03368274","phase":"PHASE4","title":"To Evaluate the Clinical Efficacy of Iguratimod in the Treatment of IgG4 Related Disease (IgG4-RD) With Mild Symptom","status":"UNKNOWN","sponsor":"Wen Zhang","startDate":"2017-09-01","conditions":["IgG4-related Disease"],"enrollment":30,"completionDate":"2018-06-01"},{"nctId":"NCT03054545","phase":"NA","title":"Iguratimod as Treatment for Refractory Lupus Nephritis","status":"UNKNOWN","sponsor":"RenJi Hospital","startDate":"2017-05-08","conditions":["Lupus Nephritis"],"enrollment":30,"completionDate":"2019-04-30"},{"nctId":"NCT03023592","phase":"PHASE1,PHASE2","title":"Study of Iguratimod in Sjögren's Syndrome","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2017-02","conditions":["Sjogren's Syndrome"],"enrollment":30,"completionDate":"2018-04"},{"nctId":"NCT01548001","phase":"PHASE4","title":"Long-term Efficacy of Iguratimod Alone or Iguratimod in Combination With Methotrexate in Patients With Rheumatoid Arthritis","status":"UNKNOWN","sponsor":"Jiangsu Simcere Pharmaceutical Co., Ltd.","startDate":"2012-05","conditions":["Rheumatoid Arthritis"],"enrollment":910,"completionDate":"2017-01"},{"nctId":"NCT02275299","phase":"PHASE4","title":"Study of Iguratimod Plus Methotrexate Compared to Leflunomid Plus Methotrexate in Patients With Rheumatoid Arthritis","status":"UNKNOWN","sponsor":"Jiangsu Simcere Pharmaceutical Co., Ltd.","startDate":"2013-09","conditions":["Rheumatoid Arthritis"],"enrollment":240,"completionDate":"2016-02"},{"nctId":"NCT01893151","phase":"PHASE4","title":"Effectiveness of Iguratimod Versus Placebo to Treat Early Rheumatoid Arthritis on MRI","status":"UNKNOWN","sponsor":"Jiangsu Simcere Pharmaceutical Co., Ltd.","startDate":"2012-07","conditions":["Rheumatoid Arthritis"],"enrollment":200,"completionDate":"2015-12"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"4IHY34Y2NV","CHEBI":"CHEBI:31689","INN_ID":"8176","UMLSCUI":"C1872427","chemblId":"CHEMBL2107455","ChEMBL_ID":"CHEMBL2107455","KEGG_DRUG":"D01146","DRUGBANK_ID":"DB12233","PUBCHEM_CID":"124246","IUPHAR_LIGAND_ID":"9736","MESH_SUPPLEMENTAL_RECORD_UI":"C519076"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":227,"therapeuticAreas":["Immunology"],"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Kolbet is a small molecule inhibitor of the macrophage migration inhibitory factor. It is a drug that belongs to the class of inhibitors.","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"JP","regulator":"PMDA","status":"approved","approval_date":"2012-06-29T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":1,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:37:09.640435+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}